Killer cell immunoglobulin-like receptors (KIRs) are transmembrane glycoproteins expressed by <1-8% NK cells and subsets of CD8+ T cells (Melero et al., 1994, The Journal of Immunology, 152(4)). KIR2DL1 or CD158a, is a 58-kDa type I transmembrane protein encoded by KIR2DL1 gene and contains two extracellular Ig-like C2-type domains (2D) and a long cytoplasmic tail (L) which transduces inhibitory signals via an immune tyrosine-based inhibitory motif (ITIM) (Konjevic et al., 2012, Immunologic Research, 52, 139–156). KIR proteins are capable to recognize MHC class I molecules on target cells and inhibit cytotoxicity and are thought to play an important role in the regulation of immune response. KIR2DL1 binds ARRB2, PTPN6, PTPN11, HLA-B and C2-group of HLA-C molecules (Van Der Ploeg et al., 2017, Front. Immunol, 8, 298.).
Our anti-KIR2DL1 antibody KIR2DL1.03 works in ELISA (on immunogen) and in FACS (on human cells).

